ABOUT US
Patient One is a coalition of academia, development experts, a pharmaceutical company and social investors, collaborating closely with patient representatives and clinical experts to develop an accessibly priced treatment for cystinosis.
MISSION
Produce a new formulation to improve cystinosis treatment options for patients.
VISION
Provide all cystinosis patients with accessible and high-standard pharmaceutical care.
PARTNERS
Patient One is a spin-off of the Fair Medicine Foundation and works according to the Fair Medicine Charter.
We are a coalition of several parties who have contributed to the research and development of a novel therapy, by investing both time and money.
There are currently six shareholders who have invested time and or money in Patient One.
Tiofarma – Dutch pharmaceutical research and development company specialised in the development and distribution of small molecules
Nierstichting Nederland – Non-profit organisation with the mission to improve the quality of life of kidney patients
Fair Medicine Foundation – Non-profit organisation with the mission to provide everyone with access to safe, effective and affordable medications
Fair Medicine Fund – Impact investment fund that invests in drug development companies that commit to developing drugs for a fair price
OUR CORE TEAM
Patient One is a collaboration of academia, development experts, a pharmaceutical company and social investors, which collaborates closely with patient representatives and clinical experts. The collaboration is led by the core team.
WILL YOU
HELP US?
To make our next steps in the development process possible, we need additional investments.
Will you join our cause?